Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of RPG Life Sciences Ltd
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 118 | 148 | 154 | 154 | 127 | 165 | 172 | 173 | 143 | 169 | 182 | 180 | 177 |
| Expenses + | 103 | 116 | 116 | 116 | 106 | 126 | 126 | 124 | 118 | 133 | 143 | 140 | 144 |
| Operating Profit | 16 | 32 | 37 | 38 | 21 | 39 | 46 | 49 | 25 | 35 | 39 | 40 | 33 |
| OPM % | 13% | 22% | 24% | 25% | 16% | 24% | 27% | 28% | 18% | 21% | 21% | 22% | 19% |
| Other Income + | 2 | 2 | 2 | 2 | 2 | 2 | -25 | 3 | 115 | 5 | 16 | -5 | 13 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 |
| Profit before tax | 14 | 30 | 35 | 36 | 18 | 36 | 15 | 47 | 135 | 35 | 49 | 29 | 40 |
| Tax % | 25% | 26% | 26% | 26% | 25% | 26% | 72% | 26% | 13% | 26% | 25% | 24% | 26% |
| Net Profit + | 10 | 22 | 26 | 26 | 13 | 27 | 4 | 35 | 117 | 26 | 37 | 22 | 30 |
| EPS in Rs | 6.26 | 13.36 | 15.64 | 16.00 | 8.01 | 16.18 | 2.54 | 21.12 | 70.95 | 15.90 | 22.28 | 13.38 | 18.08 |
Financials of RPG Life Sciences Ltd
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 242 | 279 | 294 | 344 | 330 | 376 | 389 | 440 | 513 | 582 | 653 | 708 |
| Expenses + | 228 | 256 | 274 | 306 | 296 | 315 | 318 | 353 | 408 | 453 | 493 | 560 |
| Operating Profit | 14 | 23 | 20 | 38 | 34 | 60 | 71 | 87 | 104 | 129 | 161 | 147 |
| OPM % | 6% | 8% | 7% | 11% | 10% | 16% | 18% | 20% | 20% | 22% | 25% | 21% |
| Other Income + | 1 | 1 | 18 | 1 | 1 | -5 | 1 | 3 | 4 | 7 | 95 | 29 |
| Interest | 3 | 2 | 4 | 5 | 5 | 3 | 2 | 1 | 1 | 1 | 2 | 1 |
| Depreciation | 11 | 10 | 11 | 14 | 15 | 16 | 16 | 16 | 16 | 17 | 21 | 21 |
| Profit before tax | 1 | 12 | 23 | 20 | 15 | 36 | 54 | 73 | 92 | 118 | 233 | 154 |
| Tax % | 0% | 0% | 10% | 34% | 28% | 20% | 25% | 30% | 26% | 26% | 21% | 25% |
| Net Profit + | 1 | 12 | 21 | 13 | 11 | 29 | 40 | 51 | 68 | 88 | 183 | 115 |
| EPS in Rs | 0.60 | 7.03 | 12.70 | 8.13 | 6.54 | 17.54 | 24.19 | 31.13 | 40.90 | 53.00 | 110.79 | 69.64 |
| Dividend Payout % | 132% | 23% | 22% | 30% | 37% | 23% | 30% | 31% | 29% | 30% | 22% | 34% |
Financials of RPG Life Sciences Ltd
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 112 | 120 | 134 | 142 | 147 | 163 | 203 | 243 | 294 | 362 | 517 | 592 |
| Borrowings + | 33 | 23 | 45 | 54 | 36 | 12 | 2 | 1 | 0 | 0 | 0 | 20 |
| Other Liabilities + | 39 | 49 | 55 | 82 | 54 | 78 | 85 | 88 | 112 | 138 | 127 | 168 |
| Total Liabilities | 197 | 205 | 247 | 291 | 251 | 267 | 303 | 345 | 419 | 513 | 658 | 793 |
| Fixed Assets + | 105 | 109 | 137 | 131 | 128 | 123 | 113 | 104 | 124 | 114 | 172 | 200 |
| CWIP | 1 | 2 | 2 | 9 | 17 | 10 | 12 | 31 | 25 | 96 | 16 | 20 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 58 | 91 | 127 | 120 |
| Other Assets + | 92 | 94 | 108 | 152 | 106 | 134 | 178 | 210 | 211 | 212 | 343 | 454 |
| Total Assets | 197 | 205 | 247 | 291 | 251 | 267 | 303 | 345 | 419 | 513 | 658 | 793 |
Financials of RPG Life Sciences Ltd
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -2 | 33 | 7 | 15 | 46 | 50 | 58 | 65 | 91 | 94 | 78 | 0 |
| Cash from Investing Activity + | -10 | -15 | -30 | -16 | -19 | -11 | -8 | -35 | -106 | -79 | -42 | 0 |
| Cash from Financing Activity + | 12 | -18 | 23 | 0 | -26 | -39 | -10 | -14 | -17 | -20 | -27 | 0 |
| Net Cash Flow | -0 | -0 | 1 | -1 | 0 | 0 | 40 | 17 | -32 | -5 | 9 | 0 |
| Free Cash Flow | -12 | 18 | -48 | -1 | 26 | 39 | 50 | 41 | 58 | 25 | 151 | 0 |
| CFO/OP | 14% | 150% | 58% | 48% | 144% | 94% | 94% | 96% | 111% | 96% | 81% | 0% |
Financials of RPG Life Sciences Ltd
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 48 | 49 | 72 | 43 | 62 | 54 | 27 | 27 | 31 | 48 | 60 |
| Inventory Days | 149 | 156 | 163 | 171 | 136 | 133 | 162 | 214 | 203 | 200 | 159 | 179 |
| Days Payable | 109 | 135 | 102 | 165 | 83 | 127 | 132 | 117 | 138 | 140 | 135 | 141 |
| Cash Conversion Cycle | 101 | 70 | 110 | 78 | 96 | 68 | 84 | 124 | 91 | 90 | 72 | 99 |
| Working Capital Days | 27 | 26 | 20 | 22 | 20 | 41 | 52 | 47 | 33 | 25 | 45 | 107 |
| ROCE % | 2% | 9% | 10% | 13% | 10% | 23% | 27% | 31% | 33% | 35% | 33% | 26% |